Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bevacizumab for Renal Cell Carcinoma
NCT00113217Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2005
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Progression Free Survival up to 3 years and Toxicities of therapy with bevacizumab. Started Feb 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00113217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113217.